Home LiteratureArticle Details
PMID: 20795936 Published · ppublish English Journal Article Review

Vitamin D insufficiency and diabetes risks.

Current drug targets ·Vol. 12 ·No. 1 ·2011-01-00 ·Pages 61-87

Boucher BJ

Abstract

Diabetes is an increasing epidemic; hyperglycemia results from lack of insulin or inadequate insulin secretion following increases in insulin resistance. Huge costs are placed upon sufferers and health providers, aggravated as serious and disabling complications develop. Thus, measures to reduce the diabetic burden are public health concerns. Vitamin D, identified ≈100 years ago, promotes calcium absorption and utilization, preventing and curing rickets & osteomalacia. Calcium is necessary for insulin secretion, suggesting vitamin D may contribute to maintaining insulin secretion. Vitamin D, formed in skin in bright sunshine, is scarce in foodstuffs. Data linking hypovitaminosis D to hyperglycemia, type 2 diabetes (T2DM) and metabolic disorders increasing cardiovascular risk [metabolic 'syndrome'] has accumulated over ≈40 years. Many mechanisms are known whereby hypovitaminosis D could be causal, e.g. by increasing insulin resistance, reducing insulin secretion and increasing autoimmune or inflammatory damage to pancreatic islets. Major questions still to be answered are whether increasing vitamin D status to the maximum seen in healthy people would reduce the risk of diabetes, the severity of the disease or of its complications, including cardiovascular disease. These questions urgently require answers. If on-going/ planned RCTs confirm causality, maintenance of adequate vitamin D status at the population level by food-fortification or supplementation would be cost-effective measures likely to reduce the burden and costs of diabetes to individuals and health services. Additionally, vitamin D(2/3) supplementation is cheap but whether some non-hypercalcemia-inducing analogue may prove safer has not yet been addressed at the population level.

MeSH Terms
Aging/drug effects,metabolism Animals Biomarkers Diabetes Complications/drug therapy Diabetes Mellitus/etiology,metabolism,physiopathology,prevention & control Diabetes Mellitus, Type 1/drug therapy,etiology,prevention & control Diabetes Mellitus, Type 2/drug therapy,etiology,prevention & control Dietary Supplements Fatty Liver/complications,drug therapy Food, Fortified Humans Insulin Resistance Metabolic Syndrome/drug therapy,etiology,prevention & control Nutrition Policy Nutritional Requirements Risk Vitamin D/adverse effects,analogs & derivatives,metabolism,therapeutic use Vitamin D Deficiency/blood,drug therapy,physiopathology
Chemicals
Biomarkers Vitamin D
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Boucher Barbara J
Centre for Diabetes, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, Blizard Institute of Cell and Molecular Science, Newart Street, London, E1 2AT, UK. [email protected]
Article Info
Journal
Current drug targets
Abbr.
Curr Drug Targets
ISSN
1873-5592
Published
2011-01-00
Pages
61-87
Language
English
Region
United Arab Emirates
NLM ID
100960531
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]